Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
Abdurrahmaan Ali Suei Elbuzidi, ECMO and Critical Care Consultant at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of Cardiothoracic and Vascular Anesthesia, adding:
“Excited to share that our latest systematic review and meta-analysis has been published:
‘Clinical Outcomes of Different Heparin Anticoagulation Monitoring Targets in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.’
This work explores an important and ongoing challenge in ECMO care:
What is the optimal anticoagulation monitoring target?
Despite widespread use of unfractionated heparin in ECMO, significant variability remains in monitoring strategies (ACT, aPTT, anti-Xa, and others), with potential implications for bleeding, thrombosis, and overall patient outcomes.
Our review aimed to synthesize the available evidence and evaluate how different monitoring targets may influence clinical outcomes.
Proud to have collaborated with an outstanding multidisciplinary team of colleagues on this project.Special thanks to all co-authors for their dedication and contributions.
Looking forward to continued research that helps refine anticoagulation strategies and improve outcomes for ECMO patients.”
Title: Clinical Outcomes of Different Heparin Anticoagulation Monitoring Targets in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-analysis
Authors: Alaa Rahhal, Ans Alamami, Rabee Tawel, Ahmed Shebani, Hassan Fahed El Daezli, Abdurrahmaan Elbuzidi, Nadir Kharma, Amr Omar, Ahmed Labib Shehatta

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance